Bluefish continues to grow with top best seller, omeprazol

The Swedish specialty pharma company Bluefish continues to expand its European product portfolio with two new products. One is the big selling drug omeprazol, which has now been approved in its first European market. The company is expecting approval in an additional six countries within six months.

With ten drugs that are either approved or in the registration process, Bluefish has a market of over SEK 1 billion in Sweden alone. Omeprazol is one of the biggest-selling drugs in Europe. In Sweden, omeprazol sales exceeded SEK 300 million in 2006.
An other important market in Europe for omeprazol is Italy. There, the patent for the original (Losec) will expire later in 2007.
"In Italy alone, omeprazol sales are at about SEK 2.5 billion. We may be one of the first on the market,” says CEO of Bluefish Karl Karlsson.

The company currently has ten drugs that are either approved or awaiting registration in the EU. Bluefish pharmaceuticals are manufactured in India, where Bluefish has a fully-owned subsidiary. The other drug in Bluefish’s product portfolio is sumatriptan, which is taken for migraines.

For more information, please contact: Karl Karlsson, CEO, tel: +46 (0)8 679 50 70

Bluefish Pharmaceuticals AB is a Swedish specialty pharma company. They buy or license the rights to manufacture pharmaceuticals, mainly generic products. Low prices are maintained through efficient production and distribution. Bluefish has a wholly-owned subsidiary in Chennai, India focused on product development and production. The company is owned by the founder Karl Karlsson and a number of funds and private investors.